Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Dexmedetomidine Hydrochloride Injection 200 mcg (base)/ 2 mL (100 mcg (base) /mL) single-dose vials.
The drug is indicated for sedation of intubated and mechanically ventilated patients during treatment in an intensive care setting and for sedation of non-intubated patients prior to and/or during surgical and other procedures. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
